DATE: July 23, 2019
TIME: 10:00am PDT
The tumor microenvironment is a complex network of different cell types and states that imparts distinct properties to the tumor and plays a significant role in determining the efficacy of cancer therapies. Immunotherapies in particular have demonstrated considerable therapeutic efficacy and durable response for several tumor types, however the majority of patients are resistant or relapse after initial response. More precise spatial characterization of the tumor and tumor microenvironment with high multiplexing can potentially provide critical insight into new immunotherapeutic strategies and identify new predictive biomarkers for stratifying patients most likely to benefit from immunotherapy.
Using the RNAscope® in situ hybridization (ISH) technology from Advanced Cell Diagnostics, Inc. to molecularly guide Nanostring’s GeoMx™ Digital Spatial Profiler (DSP), it is now possible to characterize the tumor and the tumor microenvironment using 1,500+ RNA probes. The single molecule and single cell capabilities of the RNAscope ISH assay allows researchers to select discreate regions of interest for high plex spatial analyses of RNA with the highly multiplexed spatial profiling capabilities of GeoMx DSP.
In this webinar we will demonstrate how RNAscope ISH assays can be combined with GeoMx DSP to assess expression of RNA from a specific regions of interest and perform follow up confirmation of target gene expression at the single-cell level, all with spatial context.
Key learning objectives:
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
WAVE Newsletter Promotion11%
Trending Newsletter Promotion1%
Medical Laboratory Technician6%
Clinical Laboratory Scientist4%
Life Science Company3%
Medical Device Company1%